Galectin‐3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients

Autor: Deborah A. Siwik, Deepa M. Gopal, Wilson S. Colucci, Noyan Gokce, Nir Ayalon, Marcello Panagia, Jill Downing, Chang Seng Liang, Aaron L. Sverdlov, Alejandro J. Perez, Courtney Donohue, Jennifer E. Ho, Vanessa Silva, Yi-Chih Wang, Vijaya B. Kolachalama, Caroline M. Apovian
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Adult
Male
medicine.medical_specialty
obesity
Follistatin-Related Proteins
Heart disease
Galectin 3
Galectins
Hypertension
Pulmonary
030204 cardiovascular system & hematology
03 medical and health sciences
0302 clinical medicine
prevention
Metabolic Diseases
remodeling heart failure
Internal medicine
Natriuretic Peptide
Brain
Medicine
echocardiography
Humans
030212 general & internal medicine
Stage (cooking)
Preventive Cardiology
Original Research
Heart Failure
Metabolic Syndrome
Pulmonary Hypertension
business.industry
Hemodynamics
Blood Proteins
Middle Aged
medicine.disease
Obesity
Pulmonary hypertension
Peptide Fragments
3. Good health
Galectin-3
Case-Control Studies
Cardiology
Female
Hypertrophy
Left Ventricular
Cardiology and Cardiovascular Medicine
business
Heart failure with preserved ejection fraction
Biomarkers
Zdroj: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
ISSN: 2047-9980
Popis: Background Obesity is a precursor to heart failure with preserved ejection fraction. Biomarkers that identify preclinical metabolic heart disease ( MHD ) in young obese patients would help identify high‐risk individuals for heart failure prevention strategies. We assessed the predictive value of GAL3 (galectin–3), FSTL3 (follistatin‐like 3 peptide), and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease. Methods and Results Asymptomatic obese patients (n=250) and non‐obese controls (n=21) underwent echocardiographic cardiac phenotyping. Obese patients were classified as MHD positive ( MHD ‐ POS ; n=94) if they had abnormal diastolic function or left ventricular hypertrophy and had estimated pulmonary artery systolic pressure ≥35 mm Hg. Obese patients without such abnormalities were classified as MHD negative (MHD‐NEG; n=52). Serum biomarkers timed with echocardiography. MHD ‐ POS and MHD‐NEG individuals were similarly obese, but MHD ‐ POS patients were older, with more diabetes mellitus and metabolic syndrome. Right ventricular coupling was worse in MHD ‐ POS patients ( P GAL 3 levels were higher in MHD ‐ POS versus MHD ‐NEG patients (7.7±2.3 versus 6.3±1.9 ng/mL, respectively; P GAL 3 and FSTL 3 levels correlated with diastolic dysfunction and increased pulmonary artery systolic pressure but not with left ventricular mass. In multivariate models including all 3 biomarkers, only GAL 3 remained associated with MHD (odds ratio: 1.30; 95% CI , 1.01–1.68; P =0.04). Conclusions In young obese individuals without known cardiovascular disease, GAL 3 is associated with the presence of preclinical MHD . GAL 3 may be useful in screening for preclinical MHD and identifying individuals with increased risk of progression to obesity‐related heart failure with preserved ejection fraction.
Databáze: OpenAIRE
Externí odkaz: